Clinical Trial Update: Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study of ramucirumab (IMC-1121B) in untreated hepatocellular carcinoma has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-07-03